EU & UK antitrust watchdogs are set to decide by this weekend whether to approve AstraZeneca’s US$39 billion bid for biopharmaceutical company Alexion, a European Commission filing revealed on Tuesday, June 1.
Anglo-Swedish drugmaker AstraZeneca sought approval for the deal on Monday. However, the UK’s competition regulator is reviewing the takeover bid for the US-based pharma firm, until July 5, looking at whether it could shrink competition in the UK or other markets.
The UK’s Competition and Markets Authority (CMA) stated that it welcomes any comments from interested parties on the deal to help its assessment, setting a deadline of June 3 for submissions.
The famed drugmaker AstraZeneca, which became a household name after its vaccine went to market, agreed to buy Alexion in December.
The eye-watering US$39 billion deal would be the vaccine makers largest-ever deal and marks a bet on the rare-disease immunology market.
The CMA review forms part of the initial analysis and is likely to be finalized by July 21, the watchdog stated.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI